Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to assets ratio is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
0.00%
DEBT TO ASSETS RATIO AVG 3Y
0.00%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 580 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$112.36M
Debt to Assets Ratio
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$113.17M
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.91M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.20M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.33M
Debt to Assets Ratio
0.21%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.08M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.53M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $112.36M | 0.00% | 0.00% | 0.00% | N/A |
| BGM Group Ltd. (BGM)vs › | $112.03M | 0.00% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.17M | 0.64% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | 0.65% | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | 0.01% | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $115.52M | 0.09% | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $108.33M | 0.21% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.08M | 0.09% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.53M | 0.09% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | 0.19% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
13.40
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 154.43% |
| 2022-09-30 | 130.67% |
| 2022-06-30 | 98.30% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
